Compare Novo Nordisk A/S (NVO) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vital Farms Inc — how do they compare? Novo Nordisk A/S trades at $46.2 (market cap $207.85B), while Vital Farms Inc trades at $11.44 (market cap $496.50M). The key difference: Novo Nordisk A/S is far larger — about 418.6× Vital Farms Inc's market cap, and Novo Nordisk A/S pays a 3.81% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals.
| NVO | VITL | |
|---|---|---|
Market Cap | $207.85B | $496.50M |
Sector | Health | Consumer Staples |
52-Week High | $63.98 | $52.41 |
52-Week Low | $35.29 | $8.28 |
Enterprise Value | $222.55B | $583.51M |
Dividend Yield | 3.81% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.
NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.
VITL trades at $11.48, up 1.95% on the day, but faces significant technical headwinds with a bearish moving average signal. The company reported mixed Q2 2026 results, beating revenue estimates but posting a $0.47 per share loss amid industry oversupply challenges. Recent $125 million term loan financing provides liquidity support during this transitional period.
While analyst consensus remains positive with a $13.00 price target, near-term risks include margin compression from elevated costs and competitive pricing pressures. The stock's attractive P/S ratio of 0.67 offers value potential if the company can navigate current industry headwinds and return to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
